MARKET

NVTA

NVTA

Invitae
NYSE

Real-time Quotes | Nasdaq Last Sale

40.59
+0.59
+1.48%
After Hours: 41.25 +0.66 +1.63% 19:38 09/21 EDT
OPEN
39.25
PREV CLOSE
40.00
HIGH
40.79
LOW
37.59
VOLUME
4.30M
TURNOVER
--
52 WEEK HIGH
40.96
52 WEEK LOW
7.42
MARKET CAP
5.36B
P/E (TTM)
-10.4310
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16)
Benzinga · 4d ago
StockBeat: Inditex, H&M Put Fashion Back in Fashion
By Geoffrey Smith
Investing.com · 5d ago
Betting on a V-Shaped Recovery, and Winning
(Bloomberg Opinion) -- Market commentators are shaking their heads. Wall Street heavyweights are dubious. Federal Reserve officials are warning about dim prospects for a robust recovery of the devastated pandemic economy. Yet even as the U.S. economy falters and Americans suffer more from Covid-19 than
Bloomberg · 6d ago
L Brands Announces Partnership with Next PLC for Victoria’s Secret UK
COLUMBUS, Ohio, Sept. 14, 2020 (GLOBE NEWSWIRE) -- L Brands, Inc. (NYSE: LB) today announced a partnership with Next PLC (LON:  NXT) for its company-owned Victoria’s Secret business in the United Kingdom and Ireland (“Victoria’s Secret U.K.”). Under the agreement, which is subject to regulatory clearance
GlobeNewswire · 09/14 20:50
Invitae Appoints Kimber Lockhart to its Board of Directors
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the appointment of Kimber Lockhart to its Board of Directors, effective September 10, 2020.
PR Newswire · 09/11 11:30
PTC Therapeutics Launches PTC PINPOINT - A Genetic Testing Program for Individuals Suspected of Having Neurotransmitter Disorders
PTC Therapeutics, Inc. (NASDAQ: PTCT) today introduced a new program that provides genetic testing and counseling for people who may have a neurotransmitter disorder, such as aromatic L-amino acid decarboxylase (AADC) deficiency. The program, called PTC PINPOINT, will offer the testing at no charge to
PR Newswire · 09/09 13:00
Morgan Stanley Initiates Coverage On Invitae with Equal-Weight Rating, Announces Price Target of $38
Morgan Stanley analyst Tejas Savant initiates coverage on Invitae (NYSE:NVTA) with a Equal-Weight rating and announces Price Target of $38.
Benzinga · 09/09 10:11
Invitae: Revolutionizing Genetic Testing
Invitae is hoping to democratize genetic testing by dramatically reducing prices.The company is rapidly expanding its business in order to cement a strong foothold in the fast-growing genetics market.Its aggressive approach does come with major near-term risks.
Seekingalpha · 09/08 08:53
More
No Data
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NVTA stock price target is 36.25 with a high estimate of 38.00 and a low estimate of 34.00.
EPS
Institutional Holdings
Institutions: 174
Institutional Holdings: 88.57M
% Owned: 67.08%
Shares Outstanding: 132.03M
TypeInstitutionsShares
Increased
71
22.07M
New
31
3.09M
Decreased
38
6.61M
Sold Out
48
4.69M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.94%
Pharmaceuticals & Medical Research
-2.24%
Key Executives
Chairman/President/Chief Executive Officer/Co-Founder/Director
Sean George
Chief Financial Officer
Shelly Guyer
Chief Operating Officer
Kenneth Knight
Chief Accounting Officer
Robert Werner
General Counsel/Secretary
Thomas Brida
Other
Robert Nussbaum
Other
Katherine Stueland
Other
Karthik Suri
Lead Director/Independent Director
Christine Gorjanc
Director
Kimber Lockhart
Independent Director
Eric Aguiar
Independent Director
Geoffrey Crouse
Independent Director
Chitra Nayak
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average NVTA stock price target is 36.25 with a high estimate of 38.00 and a low estimate of 34.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NVTA
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company's products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of InVitae Corp stock information, including NYSE:NVTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVTA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVTA stock methods without spending real money on the virtual paper trading platform.